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Effectiveness of osimertinib in patients with lung adenocarcinoma 
in clinical practice — the Expanded Drug Access Program in Poland
Abstract
Introduction: Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 
that has demonstrated efficacy in the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC) in prospective clinical trials. 
Material and methods: This retrospective analysis evaluated the outcomes of 32 pretreated patients with EGFR T790M mutation 
who received osimertinib in clinical practice at seven centers in Poland within the Expanded Drug Access Program. Osimertinib 
was used in the second line in 59% of patients and in later lines in 41%. 
Results: Objective response was attained in 16 patients (50%), and 12 subjects (38%) had stable disease. Median progression
-free survival was 11.3 months in the overall population, 12.6 months in patients with EGFR exon 19 mutation and 7.5 months in
patients with EGFR exon 21 mutation (p = 0.045). Median overall survival (OS) was 18.3 months. Overall, 58.4% and 45.6% of
patients remained in follow-up after 12 and 24 months, respectively. Median OS appeared longer for patients without cerebral me-
tastases than for those with cerebral metastases (27.4 vs 9.4 months, respectively; p = 0.078), and for patients with the Eastern 
Cooperative Oncology Group performance status (ECOG PS) 0–1 than those with ECOG PS 2 (27.4 vs 11.8 months, respectively;
p = 0.189), although neither result reached statistical significance. Median OS of patients with partial response, stable disease
and progressive disease was 27.4, 12.7 and 4.5 months, respectively (p < 0.001). Age, comorbidities, line of treatment with
osimertinib, and type of activating EGFR mutation did not impact on OS. Adverse events of any grade or grade 3/4 were reported 
in 38% and 9% of patients, respectively. One person discontinued due to interstitial pneumonia.
Conclusion: These results confirm the value of osimertinib in patients with previously treated EGFR T790M-mutant NSCLC.
Clinical benefit was evident in patients with cerebral metastases and moderate performance status.
Key words: non-small-cell lung cancer, epidermal growth factor receptor tyrosine kinase inhibitor, T790M mutation, osimertinib, 
clinical practice
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Introduction
Advanced non-small-cell lung cancer 
(NSCLC) remains a disease of poor prognosis. The 
effectiveness of chemotherapy is limited: overall 
response rates (ORRs) do not exceed 25–30%, 
and median overall survival (OS) is 10–12 mon-
ths [1]. Patients whose tumors harbor activating 
mutations in the epidermal growth factor receptor 
(EGFR) gene — most of whom have adenocarcino-
ma — comprise a clinically important subgroup. 
The prevalence of EGFR mutation varies accor-
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ding to ethnicity and is estimated at 30–45% in 
Asian patients and 10–20% in Caucasian patients 
[1]. The prognosis of this molecularly selected 
subgroup of patients has significantly improved 
with the introduction of EGFR tyrosine kinase 
inhibitor (TKI) drugs. In first-line treatment, 
erlotinib, gefitinib or afatinib provide an ORR 
of approximately 60% and a median progres-
sion-free survival (PFS) of around 10–12 months 
[2–4], while dacomitinib and osimertinib yield 
a median PFS of approximately 18 months [5, 6]. 
Until recently, the treatment of choice for 
disease progression during EGFR TKI therapy was 
chemotherapy with platinum-based drugs. Howe-
ver, identification of the molecular mechanisms 
responsible for resistance to anti-EGFR treatment 
has allowed the development of novel drugs tar-
geting resistant tumors. Currently, osimertinib is 
the only agent approved for use in this setting.
Osimertinib is a third-generation, irrever-
sible EGFR TKI. It has demonstrated significant 
benefit vs platinum-based chemotherapy after 
failure of first- or second-generation EGFR TKIs 
in patients whose tumors harbor the T790M re-
sistance mutation, of whom 60% showed primary 
TKI sensitivity [7, 8]. Furthermore, osimertinib is 
also characterized by high activity in the first-line 
treatment of subjects with activating EGFR muta-
tion-positive tumors [6]. 
This paper reports the outcomes of osimerti-
nib treatment in patients with advanced NSCLC 
with confirmed EGFR T790M mutation after di-
sease progression during EGFR TKI therapy. Tre-
atment was carried out as a part of the Expanded 
Drug Access Program prior to reimbursement of 
the osimertinib in Poland.
Material and methods
Eligibility criteria
The study included 32 patients who quali-
fied for treatment with osimertinib as a part of 
the Expanded Drug Access Program at seven 
cancer centers in Poland between July 2016 and 
March 2018. Eligible patients had a diagnosis of 
advanced NSCLC at stage IV or stage IIIB (with 
no radical treatment options), confirmed EGFR 
T790M mutation, measurable lesions, age > 
18 years, Eastern Cooperative Oncology Gro-
up performance status (ECOG PS) 0–2, normal 
laboratory indicators of renal, hepatic and he-
matopoietic function, and absence of clinically 
active secondary central nervous system (CNS) 
lesions. Patients with a history of interstitial 
lung disease, radiation pneumonitis requiring 
glucocorticosteroid use, electrocardiogram abnor-
malities or risk factors for QT prolongation were 
not eligible for treatment.
Osimertinib was administered at a daily 
dose of 80 mg until progressive disease (PD) was 
confirmed, unacceptable toxicity occurred, or 
a patient’s consent was withdrawn. Response 
assessment was based on computed tomography 
(CT) performed approximately every 8 weeks.
Before starting the treatment, patients signed 
an informed consent form for osimertinib therapy. 
Study objectives and outcomes
The aim of the study was to assess the effica-
cy and safety of osimertinib in patients diagnosed 
with advanced NSCLC and T790M mutation after 
failure of previous systemic treatment. Treatment 
outcomes were retrospectively evaluated using 
available medical documentation. Radiological 
images were not reassessed for the purposes of 
this study.
Response was assessed according to Respon-
se Evaluation Criteria in Solid Tumors v. 1.1. In 
addition, PFS was evaluated as the duration from 
osimertinib initiation until documented radiolo-
gical/clinical disease progression or death. OS 
was defined as the duration from the initiation 
of osimertinib until death. The study also asses-
sed the prognostic value of selected clinical and 
molecular factors: age; gender; ECOG PS; smo-
king status; previous cancer treatment; presence 
of cerebral metastases; type of EGFR activating 
mutation; and response to previous treatment. 
The safety of the drug was analyzed by evalu-
ation of adverse reactions, which were classified 
according to the Common Terminology Criteria 
for Adverse Events v. 4.0.
Statistical methods
PFS and OS were analyzed using Ka-
plan-Meier estimators. Results are presented as 
median survival and 12- and 24-month survival 
rates. The log-rank test was used to compare PFS 
and OS between subgroups defined basing on the 
analyzed clinical and molecular variables. A si-
gnificance level (alpha) of 0.05 was applied in all 
calculations. Analyses were conducted using the 
R statistical program v. 3.5.1 (2018; R Foundation 
for Statistical Computing, Vienna, Austria).
Results
Patient population
A total of 32 patients were included in the 
study. At the time of the analysis, 15 subjects 
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remained in follow-up, of whom 7 persons conti-
nued to receive osimertinib. The median duration 
of follow-up since the initiation of the treatment 
was 40.9 months.
Table 1 summarizes key patient characteri-
stics at the start of osimertinib therapy. Overall, 
15 patients (47%) had never smoked, while 
12 subjects (38%) were past smokers and 2 in-
dividuals (6%) were current smokers. A total of 
17 patients (53%) had documented comorbidities, 
the most common of which was hypertension 
(11 patients; 34%). All patients subjects had a dia-
gnosis of lung adenocarcinoma. Twenty patients 
(63%) had stage IV disease at diagnosis, while the 
remaining patients (n = 12; 38%) were diagno-
sed at stages I–IIIB and had previously received 
treatment with radical intent prior to diagnosis 
of advanced disease. Between initial diagnosis 
and eligibility for the osimertinib treatment, 
8 patients (25%) had secondary changes within 
the CNS for which they had received palliative 
brain irradiation.
Previous treatment
All study subjects had received systemic tre-
atment prior to the initiation of osimertinib. Most 
patients (59%) had received one line of prior sys-
temic treatment with a first- or second-generation 
EGFR TKI (erlotinib, 53%; afatinib, 33%; gefitinib, 
10%; dacomitinib, 3%). The most common types 
of activating mutation in the EGFR gene were exon 
19 deletions (71%). Among 30 patients with docu-
mented response assessments during prior EGFR 
TKI therapy, 25 individuals (83%) had achieved 
response to treatment. After EGFR TKI treat-
ment, 13 patients (40%) received chemotherapy, 
which mostly consisted of platinum-containing 
regimens. Liquid biopsy was used to confirm the 
presence of the T790M mutation in most cases 
(27 patients; 84%).
Effectiveness
Response. Response to the treatment was 
evaluated in all 32 study subjects (Table 2). Ob-
jective response was documented in 16 patients 
(50%), while 12 patients (38%) attained stable 
disease (SD). A total of 28 patients (88%) there-
fore obtained clinical benefit. In 4 patients (13%), 
progressive disease (PD) was reported as the best 
response to treatment. Among the 8 patients with 
CNS lesions, 1 individual (13%) achieved com-
plete regression of lesions, 4 patients had partial 
response (PR; 50%) and 3 patients had SD (38%) 
within the CNS. 
There was no effect of selected clinical/mole-
cular factors (age, smoking status, ECOG PS, and 
type of activating EGFR mutation) on the ORR to 
osimertinib treatment.
Of the 25 patients who discontinued osimer-
tinib, PD data were available in 23 cases. The 
most frequent sites of PD were the lungs (50%) 
Table 1. Patient characteristics at the initiation of osimertinib
Patients (n = 32)
Median age (range), years 64 (37–82)
Gender, n (%)
Male
Female
13 (41)
19 (59)
ECOG PS, n (%)
0
1
2
3 (9)
19 (59)
10 (31)
Type of EGFR activating mutation, n (%)
Del 19
L858R
Other 
22 (69)
8 (25)
1 (3)
Smoking history, n (%)
Never 
Past smoker 
Current smoker
Missing
15 (47)
12 (38)
2 (6)
3 (9)
Location of metastatic lesions, n (%)
Lungs
CNS
Liver
Bone
Adrenal glands 
17 (53)
8 (25)
6 (19)
8 (25)
2 (6)
Number of prior treatment lines, n (%)
1
2
3
4
19 (59)
5 (16)
5 (16)
2 (6)
CNS — central nervous system; Del 19 — exon 19 deletion; ECOG PS — 
Eastern Cooperative Oncology Group performance status; EGFR — epidermal 
growth factor receptor
Table 2. Response to treatment with osimertinib
Patients, n (%)
Overall response (n = 32)
PR
SD
PD
16 (50)
12 (38)
4 (13)
Response of CNS lesions (n = 8)
CR
PR
SD
1 (13)
4 (50)
3 (38)
CR — complete response; PD — progressive disease; PR — partial response; 
SD — stable disease
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and liver (15%). Progression within the CNS was 
observed in 2 patients (including 1 individual 
with symptomatic brain metastases who had 
previously received radiotherapy to the brain). 
After PD, 6 patients (24%) received another line 
of systemic treatment, while 13 subjects (44%) 
received only best supportive care or palliative 
irradiation. Data on post-progression therapy 
were unavailable for the remaining 6 patients.
Progression-free survival. At the time of the 
analysis, 15 patients (47%) were still alive and 
7 patients (22%) were still receiving osimertinib. 
Median PFS was 11.3 months. The proportions of 
patients who remained alive and without signs 
of PD were 49.2% at 12 months and 17.0% at 
24 months.
Age, comorbidities, osimertinib treatment 
line, and type of prior EGFR TKI therapy had no 
impact on PFS. However, a correlation between 
PFS and the type of activating EGFR mutation was 
shown: median PFS was 12.6 months in patients 
with exon 19 deletions, compared with 7.5 months 
in those with exon 21 point mutations (p = 0.045; 
Figure 1). The prognostic value of the type of ac-
tivating mutation was also shown in terms of PFS 
rates at 12 months (exon 19 deletions, 54%; exon 
21 point mutations, 17%) and 24 months (exon 
19 deletions, 14%; exon 21 point mutations, 0%). 
In addition, response to prior first- and se-
cond-generation EGFR TKI treatment also de-
monstrated prognostic value (Figure 2). In pa-
tients with objective response to prior treatment, 
median PFS during osimertinib treatment was 
12.6 months. Two patients with PD as the best 
response to previous EGFR TKI therapy did not 
benefit from osimertinib: PD was documented 
in the first CT examination performed 2 months 
after the start of therapy (p < 0.001).
Overall survival. Median OS was 18.3 mon-
ths. The percentage of patients who remained 
in follow-up after 12 and 24 months of therapy 
was 58.4% and 45.6%, respectively. Age, comor-
bidities, osimertinib treatment line, and type of 
activating EGFR mutation had no effect on OS. 
However, response to osimertinib demonstrated 
prognostic value: median OS was 27.4 months in 
the subjects with PR, 12.7 months in patients with 
SD, and 4.5 months in patients with PD as the 
best response to treatment (p < 0.001; Figure 3). 
Response to the prior first- and second-gene-
ration EGFR TKI treatment also had a significant 
prognostic impact on OS following the osimer-
tinib treatment. Median OS was 18.3 months in 
patients with objective response to prior treat-
ment (n = 25), whereas the 2 individuals with 
PD during previous anti-EGFR treatment had OS 
times of 2.5 and 4.0 months (p < 0.001; Figure 4).
The impact of ECOG PS at the time of qu-
alification for osimertinib on survival rates was 
also analyzed. Patients with very good and good 
performance score (ECOG PS 0–1) had longer me-
dian OS (27.4 months) than those with moderate 
performance score (ECOG PS 2; 11.8 months). 
However, the observed difference was not stati-
Figure 1. PFS curves according to type of activating EGFR mutation. 
Del 19 — exon 19 deletion; EGFR — epidermal growth factor receptor; 
Point 21 — exon 21 point mutation; PFS — progression-free survival
Figure 2. PFS curves according to response to prior TKI therapy. CR — 
complete response; PD — progressive disease; PFS — progression-free 
survival; PR — partial response; SD — stable disease; ND — no data
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stically significant (p = 0.159; Figure 5).
The presence of cerebral metastases also 
impacted on the course of the disease. Patients 
without secondary brain lesions lived longer 
than those with documented brain lesions, with 
median OS of 27.4 and 9.4 months, respectively 
(p = 0.078; Figure 6).
Due to the small size of the patient popula-
tion, no multifactorial analysis was performed. 
Univariate analyses assessing the prognostic va-
lue of selected clinical and molecular factors in 
terms of OS are summarized in Table 3. Survival 
parameters for the overall group are presented 
in Table 4. 
Safety
Adverse events were reported at any grade 
for 12 patients (38%) and at grade 3/4 for 3 pa-
tients (9%; Table 5). In total, 6 study subjects 
(18%) had skin lesions and 3 patients (9%) had 
diarrhea. Other adverse events each occurred in 
Figure 3. OS curves according to response to osimertinib. OS — 
overall survival; PD — progressive disease; PR — partial response; 
SD — stable disease
Figure 4. OS curves according to response to previous first- or second-
generation EGFR TKIs. CR — complete response; EGFR — epidermal 
growth factor receptor; OS — overall survival; PD — progressive 
disease; PR — partial response; SD — stable disease; TKI — tyrosine 
kinase inhibitor
Figure 5. OS curves according to ECOG PS. ECOG PS — Eastern Co-
operative Oncology Group performance status; OS — overall survival
Figure 6. Overall survival (OS) curves according to the presence of 
secondary lesions in the CNS
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Table 3. The prognostic value of selected parameters in terms of OS
Median OS, months P-value
ECOG PS: 0–1 vs 2 27.4 vs 11.8 0.189
Age: < 60 years vs ≥ 60 years 27.4 vs 12.7 0.686
CNS metastases: present vs absent 27.4 vs 9.4 0.078
Bone metastases: present vs absent 27.4 vs 11.9 0.089
Liver metastases: present vs absent 12.1 vs 9.4 0.160
Response to osimertinib: CR/PR vs PD 27.4 vs 4.5 < 0.001
Response to prior first- or second-generation EGFR TKIs: CR/PR vs PD 18.3 vs 3.2 < 0.001
Type of EGFR mutation: Del 19 vs L858R 18.3 vs 12.1 0.379
Line of osimertinib treatment: second vs third or later 27.4 vs 9.9 0.088
CR — complete response; ECOG PS — Eastern Cooperative Oncology Group performance status; EGFR — epidermal growth factor receptor; OS — overall survival; 
PD — progressive disease; PR — partial response; TKI — tyrosine kinase inhibitor
Table 4. PFS and OS in the analyzed group of patients
Median, months 12-month rate, % 24-month rate, %
PFS 11.3 49.2 17.0
OS 18.3 58.4 45.6
OS — overall survival; PFS — progression-free survival
Table 5. Adverse reactions to osimertinib (n = 32)
Patients, n (%)
Any grade Grade 3/4
All adverse events 12 (38) 3 (9)
Skin lesions 6 (19) –
Diarrhea 3 (9) 2 (6)
Interstitial pneumonia 1(3) 1 (3)
Elevated activity of liver enzymes 1 (3) –
1 individual [interstitial pneumonia, elevated 
activity of liver enzymes, and “other” (no further 
data available)]. Clinically significant side effects 
included interstitial pneumonia (1 patient) and 
diarrhea (2 patients). In 4 subjects (13%), adverse 
events led to treatment interruption. The patient 
with interstitial pneumonia associated with osi-
mertinib permanently discontinued treatment. 
There were no treatment-related deaths.
Discussion
This report describes treatment outcomes 
with osimertinib in 32 patients diagnosed with 
advanced lung adenocarcinoma and documented 
activating T790M EGFR mutation after failure of 
first- or second-generation EGFR TKI therapy. 
Treatment was carried out in routine clinical 
practice in the general patient population and 
not as part of a clinical trial. At the time of the 
analysis, 15 patients (47%) were still alive and 
7 patients (22%) were still receiving osimertinib.
Clinical benefit was observed in 88% of the 
study subjects and PR in 50% of patients. The 
ORR is slightly lower than in the AURA2 study 
and other reports [6–8], which could be explained 
by less precise assessment of CT results in clinical 
practice compared with clinical trials — ORR 
was evaluated basing on medical documentation 
and less strict qualification to EAP comparing to 
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the clinical trials. The very high proportion of 
patients with clinical benefit is consistent with 
other reports and confirms the efficacy of osimer-
tinib in patients with T790M-positive NSCLC. 
No correlation was found between treatment re-
sponse and the clinical factors analyzed. In case 
of the patients with documented PD as the best 
response to osimertinib, the presence of other 
concomitant mechanisms of resistance to TKI 
EGFR treatment, apart from the T790M mutation, 
should be considered [9].
In the analyzed group, a relationship was 
demonstrated between the type of activating 
mutation in the EGFR gene found initially and 
the duration of response to osimertinib. More 
favorable outcomes were observed in patients 
with exon 19 deletions than in those with exon 
21 point mutations (median PFS, 12.6 vs 7.5 mon-
ths, respectively). Recently published, updated 
results from patients treated with osimertinib 
in two phase II studies also showed the type 
of activating EGFR mutation to be a prognostic 
factor [10]. In that analysis, patients with exon 
19 deletions derived a greater benefit than indi-
viduals with exon 21 mutation in terms of ORR 
(70% vs 57%), median PFS (11.1 vs 9.5 months) 
and median OS (29.1 vs 21.4 months) [10]. The 
current study also provided some evidence that 
the type of activating mutation impacted on OS, 
although the difference was not statistically si-
gnificant. In another analysis based on a larger 
group of osimertinib-treated patients in clinical 
practice, median OS was significantly longer in 
subjects with exon 19 deletions than in patients 
with exon 21 mutations (23.1 vs 15.3 months; p 
= 0.03) [11].
We observed a relationship between respon-
se to osimertinib and OS in the present study. 
Similar conclusions have been presented from an 
analysis of 27 patients treated in clinical practice 
[12]. The median OS of patients who achieved 
objective response to treatment was 24.2 months 
vs 13.5 months in the group of patients with SD 
or PD.
In the current study, 10 patients (31%) had 
ECOG PS 2 at the time of qualification for osi-
mertinib treatment. The collecting of data on the 
efficacy and safety of the drug in this group of 
patients is particularly important, because only 
individuals with ECOG PS 0 or 1 are usually 
qualified for therapy in the clinical trials. Poor 
performance status seems to be a negative progno-
stic factor in patients receiving EGFR TKIs. In our 
dataset, median OS appeared longer in patients 
with ECOG PS 0–1 than in those with ECOG PS 
2 (27.4 vs 11.8 months, respectively), although 
the difference was not statistically significant. 
Data from the GIOTAG observational study, which 
evaluated sequential treatment with afatinib 
and osimertinib in 204 patients, also indicate 
that worse performance status is associated with 
poorer outcomes [13]. Median duration of the 
sequential treatment strategy was 31.3 months 
in patients with ECOG 0–1 and 22.2 months in 
patients with ECOG ≥ 2 (p < 0.001) [13]. Recen-
tly, results of osimertinib treatment in a group 
of 30 patients with moderate performance status 
(ECOG 2–3) have been published, in which 53% 
of patients attained objective responses to treat-
ment and median PFS was 8.2 months [14]. The 
majority of the subjects (63%) had an improve-
ment in their general condition and the rates of 
adverse reactions and treatment-related deaths 
were in line with expectations based on other 
reports in the literature. In a separate analysis of 
the efficacy and safety of osimertinib in a group 
of 12 patients (out of 51 in total) with a moderate 
performance status (ECOG 2–3), the prognostic 
value of patient fitness was not specifically eva-
luated, but the authors emphasized that almost 
all subjects with ECOG 2–3 had clinical benefit 
from treatment [15].
Cerebral metastases are a significant clini-
cal problem in EGFR mutation-positive NSCLC 
that are estimated to affect approximately 20% 
of patients at diagnosis and almost 60% at some 
point during the course of their disease [16]. The 
treatment of choice is whole-brain radiotherapy 
(WBRT) or, if possible, local treatment using ste-
reotactic radiotherapy or surgery. Due to its high 
CNS penetration, osimertinib could be a relevant 
treatment option in this setting [17]. Supporting 
clinical data are provided by the FLAURA study 
of first-line osimertinib in a subgroup analysis 
of patients with CNS lesions at baseline. In that 
subgroup, osimertinib was associated with an 
ORR in the CNS of 66% (compared with 43% 
with gefitinib) [18]. Osimertinib also significantly 
reduced the risk of progression of CNS lesions 
(median CNS PFS not reached with osimertinib 
vs 13.8 months with gefitinib; hazard ratio, 0.48). 
In that study, brain imaging was not mandatory 
for all patients and was performed only in those 
with clinical suspicion of secondary CNS le-
sions. Only 25% of patients with confirmed CNS 
lesions had previous radiotherapy to the CNS; 
the remaining subjects were qualified for the 
osimertinib treatment.
In the Expanded Access Drug Program, pa-
tients with CNS lesions are required to receive 
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local treatment and demonstrate complete con-
trol of symptoms to be eligible for osimertinib 
and other EGFR TKIs. In the current study, CNS 
were identified at some point after diagnosis in 
8 patients, all of whom had prior local treatment 
(WBRT) and derived clinical benefit from sub-
sequent osimertinib therapy. However, it should 
be emphasized that CNS imaging was not manda-
tory and the data presented may not be complete.
Summary
The present study confirms the efficacy and 
safety of osimertinib in patients with NSCLC after 
EGFR TKI failure. Clinical benefit was obtained 
by patients with the T790M mutation in both the 
second and subsequent lines of treatment, as well 
as in the subjects with secondary CNS lesions 
and moderate performance status. The type of 
activating mutation present at initial diagnosis 
showed prognostic value for PFS, while response 
to osimertinib treatment and response to prior TKI 
therapy both had an effect on OS.
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